

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Tirzepatide for treating type 2 diabetes ID3938

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> Eli Lilly (tirzepatide) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> BEMDA: Black and Ethnic Minority Diabetes Association Black Health Agency Diabetes Research and Wellness Foundation Diabetes UK InDependent Diabetes Trust Network of Sikh Organisations South Asian Health Foundation Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> Association for the Study of Obesity Association of British Clinical Diabetologists British & Irish Hypertension Society British Association for Nursing in Cardiovascular Care British Geriatrics Society British Heart Foundation National Metabolic Biochemistry Network Primary Care Diabetes Society Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for Endocrinology TREND UK UK Clinical Pharmacy Association <p><u>Others</u></p>	<p><u>General commentators</u></p> <ul style="list-style-type: none"> All Wales Therapeutic and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Diabetes UK Cymru Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee <p><u>Possible comparators</u></p> <ul style="list-style-type: none"> Amring (glibenclamide) AstraZeneca (dapagliflozin, exenatide, saxagliptin) Boehringer Ingelheim (empagliflozin, linagliptin) Eli Lilly (dulaglutide, insulin) Merck Sharp & Dohme (sitagliptin) Napp Pharmaceuticals (canagliflozin) Novartis Pharmaceuticals (vildagliptin) Novo Nordisk (insulin, liraglutide) Pfizer (glipizide) Sanofi (insulin, lixisenatide) Takeda UK (alogliptin) <p><u>Relevant research groups</u></p>

Provisional stakeholder list for the health technology evaluation of tirzepatide for treating type 2 diabetes ID3938

Issue date: March 2022

<ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bury CCG • NHS England • NHS Luton CCG • Welsh Government 	<ul style="list-style-type: none"> • Cochrane Metabolic & Endocrine Disorders Group • Cochrane UK • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency
--	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the final draft guidance.

All non-company consultees are invited to submit a statement, respond to consultations, nominate clinical or patient experts and have the right to appeal against the final draft guidance.

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the final draft guidance for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.